Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Chi-Med
Biotech
Chi-Med's surufatinib fends off pancreatic tumors in phase 3
Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.
Nick Paul Taylor
Sep 18, 2020 6:05pm
Chi-Med stops pivotal pancreatic cancer trial upon early success
Jan 21, 2020 8:30am
AstraZeneca dumps phase 3 renal cell carcinoma program
Oct 24, 2019 7:20am
ASCO: Chi-Med touts fruquintinib's phase 3 safety edge
Jun 5, 2017 6:24pm
Lilly, Chi-Med cancer drug hits phase 3 goals, eyes China NDA
Mar 3, 2017 4:17am
